+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Toxicity of bevacizumab in combination with chemotherapy in older patients



Toxicity of bevacizumab in combination with chemotherapy in older patients



Oncologist 18(4): 408-414



Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. Little is known about factors associated with receipt of bevacizumab, or whether bevacizamab is associated with increased toxicity when added to chemotherapy. We conducted a prospective study of patients aged ≥65 years, which evaluated the association between geriatric assessment (GA) metrics and chemotherapy toxicity. We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. From a total of 207 patients, 27 (13%) received bevacizumab plus chemotherapy and 180 (87%) received chemotherapy alone. Groups were similar in sociodemographic and cancer characteristics. There were no baseline differences in GA domains except that patients with heart disease were less likely to receive bevacizumab (4% vs. 26%, p = .01). Seventy-eight percent of patients who had bevacizumab had grade 3-5 toxicity compared to only 57% who received chemotherapy alone (p = .06). Patients receiving bevacizumab were more likely to develop grade 3 hypertension than those who received chemotherapy alone (15% vs. 2%, p < .01). In multivariable analysis, factors associated with grade 3 or more toxicity included: bevacizumab (OR: 2.86, p = .04), CRC (OR: 2.54, p < .01), and baseline anemia (OR: 2.58, p = .03). Heart disease was more common in those who did not receive bevacizumab. Older patients who receive bevacizumab with chemotherapy have a higher odds of developing a grade 3-5 toxicity compared with those who receive chemotherapy alone.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036845330

Download citation: RISBibTeXText

PMID: 23576485

DOI: 10.1634/theoncologist.2012-0351


Related references

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Investigational New Drugs 31(1): 183-191, 2013

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Research 34(2): 949-954, 2014

A Retrospective Analysis of Efficacy and Toxicity of Bevacizumab in Combination with Chemotherapy for the Management of Nsclc in Bangladeshi Population. Anwer Khan Modern Medical College Journal 8(1): 10-16, 2017

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Annals of Oncology 21(2): 297-304, 2010

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). Bmc Cancer 16: 69, 2016

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leukemia and Lymphoma 53(4): 718-720, 2012

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. European Journal of Cancer 97: 16-24, 2018

Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. European Journal of Haematology 79(5): 398-404, 2007

Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report. Molecular and Clinical Oncology 7(3): 391-394, 2017

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of Oncology 24(9): 2342-2349, 2014

Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer. Clinical Colorectal Cancer 12(3): 204-213.E1, 2014

Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Seminars in Oncology 33(5 Suppl 10): S8-14, 2006

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer 82(2): 276-281, 2014

Efficacy and toxicity of addition of bevacizumab to chemotherapy in patients with metastatic colorectal cancer. Combinatorial Chemistry & High Throughput Screening 2019, 2019

The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer. Clinical Ovarian Cancer 4(1): 34-37, 2011